Innoventric Gains $28.5M Funding to Transform Heart Treatment

Amir Danino, Innoventric CEO

Israel’s Innoventric has raised $28.5 million in a Series B round to support the development of its innovative cross-caval treatment for tricuspid regurgitation (TR), a condition that disrupts heart function by impairing blood flow. The funding round was led by RA Capital Management, with new investment from the European Investment Committee (EIC) and continued support from BRM Group, JG Private Equity, and Mivtach Shamir Holdings. This latest investment boosts Innoventric’s total funding to $41 million since its founding in 2017.

Innoventric’s device offers a novel approach by anchoring a prosthetic valve to the vena cava rather than directly to the heart, providing a safer and less complex implantation option. This design aims to prevent common issues like leakage or detachment, making the procedure accessible for patients previously deemed unsuitable for tricuspid interventions. The streamlined process also eliminates the need for general anesthesia and echocardiography, allowing for faster patient recovery and higher success rates.

"Our mission is to revolutionize tricuspid regurgitation care with minimally invasive therapies that significantly improve patient outcomes,” said Innoventric CEO Amir Danino, highlighting the strong investor support and the promising potential of their approach.

Source: James Spiro / CTech